Loading...

ALT ALTIMMUNE INC Product Launches 8-K Filing

LTMM

LT

ALTIMMUNE INC

(ALT)

2025 8-K

Financial Results Report

Annual Meeting Announcement

Funding Announcement

Positive Trial Results

Management Transition

New Equity Offering

Loan Agreement Update

Management Change

Annual Meeting Results

Clinical Trials

Debt-Equity Swaps

New Indications

Management Change

Board Appointments

Financial Results

CFO Appointment

Annual Meeting Results

Earnings Reports

Appointment of Acting CFO

Earnings Reports

Financial Results and Obesi...

Obesity trial results

Earnings Reports

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

Appointment of Director

Earnings Reports

External Links:

On March 13, 2025, Altimmune, Inc. announced plans to pursue two new indications for its product pemvidutide: Alcohol Use Disorder (AUD) and Alcohol-Associated Liver Disease (ALD), with Phase 2 trials expected to start in 2025 involving around 100 subjects each.

AI Assistant

ALTIMMUNE INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.